Furosemide Patent Expiration
Furosemide is Used for treating congestion due to fluid overload in adults with NYHA class II/III chronic heart failure. It was first introduced by Validus Pharmaceuticals Llc
Furosemide Patents
Given below is the list of patents protecting Furosemide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lasix Onyu | US12403120 | Pharmaceutical Compositions Of Furosemide And Uses Thereof | Jan 10, 2042 | Sq Innovation |
| Furoscix Readyflow (autoinjector) | US11497755 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide | Jan 30, 2040 | Scpharmaceuticals |
| Furoscix Readyflow (autoinjector) | US11559535 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide | Jan 30, 2040 | Scpharmaceuticals |
| Furoscix Readyflow (autoinjector) | US11571434 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide | Jan 30, 2040 | Scpharmaceuticals |
| Furoscix Readyflow (autoinjector) | US11998555 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same | Jan 30, 2040 | Scpharmaceuticals |
| Furoscix Readyflow (autoinjector) | US12048709 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same | Jan 30, 2040 | Scpharmaceuticals |
| Furoscix Readyflow (autoinjector) | US12491193 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same | Jan 30, 2040 | Scpharmaceuticals |
| Furoscix Readyflow (autoinjector) | US12491194 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same | Jan 30, 2040 | Scpharmaceuticals |
| Furoscix Readyflow (autoinjector) | US12491195 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same | Jan 30, 2040 | Scpharmaceuticals |
| Furoscix Readyflow (autoinjector) | US12491196 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same | Jan 30, 2040 | Scpharmaceuticals |
| Furoscix Readyflow (autoinjector) | US12491197 | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same | Jan 30, 2040 | Scpharmaceuticals |
| Lasix Onyu | US11246851 | Pharmaceutical Compositions Of Furosemide And Uses Thereof | Jan 03, 2040 | Sq Innovation |
| Lasix Onyu | US12318363 | Pharmaceutical Compositions Of Furosemide And Uses Thereof | Jan 03, 2040 | Sq Innovation |
| Furoscix | US10272064 | Pharmaceutical formulations for subcutaneous administration of furosemide | Apr 03, 2034 | Scpharmaceuticals |
| Furoscix | US11433044 | Pharmaceutical formulations for subcutaneous administration of furosemide | Apr 03, 2034 | Scpharmaceuticals |
| Furoscix | US12370168 | Pharmaceutical Formulations For Subcutaneous Administration Of Furosemide | Apr 03, 2034 | Scpharmaceuticals |
| Furoscix | US9884039 | Pharmaceutical formulations for subcutaneous administration of furosemide | Apr 03, 2034 | Scpharmaceuticals |
About Veterinary Furosemide
Furosemide is used in drugs marketed by 7 different companies: Zyvet Animal Health Inc, Bimeda Animal Health Ltd, Elanco Us Inc, Intervet Inc, Boehringer Lngelheim Animal Health Usa Inc, Cronus Pharma Specialities India Private Ltd, First Priority Inc.
Other drugs containing Furosemide are: Salix tablets , Furosemide syrup 1% , Disal , Salix
Furosemide Petitions
Details of Furosemide's suitability petitions are listed below.
| Petitioner | Action | Date of Action | Description |
|---|---|---|---|
 | |||
| Tyler Group, Inc. | Approved | ||
Furosemide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Furosemide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005) | Merck Sharp & Dohme LLC | NA |
COMPLETED
(Aug 1, 2026)
| PHASE1 |
| Outpatient Hypertonic Saline and Loop Diuretic Combination Therapy in Cardiorenal | University of Monastir | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE3 |
| Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans | Vanderbilt University Medical Center | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure | University of Texas Southwestern Medical Center | NA |
NOT YET RECRUITING
(May 1, 2026)
| PHASE3 |
| Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide | Sarfez Pharmaceuticals, Inc. | NA |
TERMINATED
(Apr 1, 2026)
| PHASE1 |